Accepted by Scientific community and that mimic some type of lung cancer, like NSCLC, in human (same histopathology, tumor markers, etc.). And that could be developed or maintained in most standard stabularies.
Have you looked in to the LSL-KrasG12D murine model which produces lung adenomas when an Adenovirus expressing Cre Recombinase is admistered intranasally. There is another model that expresses mutant Kras and has p53 knocked which would be represent a good metestatic lung cancer model. Hope that helps.
Well, I really ment animal models, but thanks, Mark.
Joyce, where can I get the model that expresses mutant Kras and has p53 knocked? I got a patent for the idea of using certain drug as antitumoral, and need to assay it in a lung cancer animal model. Thank you.
for the LSL-KrasG12D mice: http://mouse.ncifcrf.gov/available_details.asp?ID=01XJ6
I am not sure if the LSL-kras g12d p53 flox/flox mice are commericaily available. But I know that there are couple of groups at Johns Hopkins breeding these mice; You can contact Dr. Charles Rudin or Dr. Christian Meyer at Hopkins.
The virus administered to the mice can be purchased from Vector Biolabs :http://www.vectorbiolabs.com/Recombinant-Adenovirus/1045/Ad-CMV-Cre/Adenovirus-Cre-Recombinase
If you have anymore questions please feel free to contact me. My thesis work was based on these mice.
The 4T1 mammary carcinoma in BalbC mice is highly metastatic. If you grow it in the mammary fat pad until 5mm diameter and then resect the primary, all mice will develop lung metastases.
The PyMT mouse will develop spontaneous mammary cancers that initially hormonally dependent, but over time they lose this and become metastatic.
Very nice and translational relevant transgenic models for various driver mutations developed in MSK . Example:. Perera SA, et al.
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U SA. 2009 Jan 13;106(2):474-9.